Denosumab for Treatment of a Recurrent Cervical Giant-Cell Tumor

被引:13
|
作者
Kajiwara, Daisuke [1 ,2 ]
Kamoda, Hiroto [1 ]
Yonemoto, Tsukasa [1 ]
Iwata, Shintaro [1 ]
Ishii, Takeshi [1 ]
Tsukanishi, Toshinori [1 ,3 ]
Ohtori, Seiji [2 ]
Yamazaki, Masashi [3 ]
Okawa, Akihiko [4 ]
机构
[1] Chiba Canc Ctr, Dept Orthoped Surg, Chiba, Japan
[2] Chiba Univ, Dept Orthoped Surg, Chiba, Japan
[3] Univ Tsukuba, Dept Orthoped Surg, Ibaraki, Japan
[4] Natl Hosp Org, Chiba Med Ctr, Dept Orthoped Surg, Chiba, Japan
关键词
Cervical vertebrae; Giant cell tumor of bone; Recurrence; Denosumab;
D O I
10.4184/asj.2016.10.3.553
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
A 43-year-old male patient with C5 giant cell tumor (GCT) underwent tumor resection and anterior bone fusion of C4-C6. The tumor recurred locally 9 months after surgery with the patient complaining of neck and shoulder pain similar to his preoperative symptoms. Denosumab was administered and his pain disappeared after a two-month administration, with a sclerotic rim formation seen at the tumor site on computed tomography. He has been followed for 18 months with no evidence of tumor recurrence. Complete resection is generally recommended, but is not easy for many patients with cervical GCT because of the existence of neurovascular structures. Some patients suffer from recurrence and treatment becomes more difficult. As such, denosumab may be an efficacious option for treatment of recurrent GCT of the cervical spine, although long-term follow-up is required to monitor for presence or absence of recurrence.
引用
收藏
页码:553 / 557
页数:5
相关论文
共 50 条
  • [1] Giant-cell tumor of bone: treatment options and role of denosumab
    Singh, Arun S.
    Chawla, Neal S.
    Chawla, Sant P.
    [J]. BIOLOGICS-TARGETS & THERAPY, 2015, 9 : 69 - 74
  • [2] Denosumab Treatment of Giant-Cell Tumors
    Yavuz, G.
    Unal, E.
    Tacyildiz, N.
    Dincaslan, H.
    Tanyildiz, H. G.
    Aksoy, B. A.
    Berberoglu, M.
    Siklar, Z.
    Gordu, Z.
    Asarcikli, F.
    [J]. PEDIATRIC BLOOD & CANCER, 2018, 65 : S404 - S405
  • [3] RETRACTED ARTICLE: Denosumab treatment for progressive Enneking stage II cervical giant-cell tumor conservatively
    YiXuan Tan
    Shuhan Zhang
    Jinling Zhang
    Tao Huang
    Xiaoming Li
    Xuhui Zhou
    Jiefeng Zhang
    [J]. Functional & Integrative Genomics, 2023, 23
  • [4] Denosumab treatment for giant-cell tumor of bone: a systematic review of the literature
    Luengo-Alonso, Gonzalo
    Mellado-Romero, Maria
    Shemesh, Shai
    Ramos-Pascua, Luis
    Pretell-Mazzini, Juan
    [J]. ARCHIVES OF ORTHOPAEDIC AND TRAUMA SURGERY, 2019, 139 (10) : 1339 - 1349
  • [5] Denosumab treatment for giant-cell tumor of bone: a systematic review of the literature
    Gonzalo Luengo-Alonso
    Maria Mellado-Romero
    Shai Shemesh
    Luis Ramos-Pascua
    Juan Pretell-Mazzini
    [J]. Archives of Orthopaedic and Trauma Surgery, 2019, 139 : 1339 - 1349
  • [6] RETRACTED: Denosumab treatment for progressive Enneking stage II cervical giant-cell tumor conservatively (Retracted Article)
    Tan, YiXuan
    Zhang, Shuhan
    Zhang, Jinling
    Huang, Tao
    Li, Xiaoming
    Zhou, Xuhui
    Zhang, Jiefeng
    [J]. FUNCTIONAL & INTEGRATIVE GENOMICS, 2023, 23 (01)
  • [7] GIANT-CELL TUMOR OF THE CERVICAL SPINE
    HESS, WE
    [J]. JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 1960, 42 (03): : 480 - 484
  • [8] The Role of Denosumab Treatment in Recurrent Giant Cell Bone Tumor of the Orbit
    Gupta, Arjav
    Colwell, Bruce
    Clarke, David B.
    Massoud, Emad A.
    Croul, Sidney
    Hussain, Ahsen
    [J]. OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY, 2024, 40 (05): : e161 - e164
  • [9] Denosumab: a breakthrough in treatment of giant-cell tumour of bone?
    Balke, Maurice
    Hardes, Jendrik
    [J]. LANCET ONCOLOGY, 2010, 11 (03): : 218 - 219
  • [10] Current management of giant-cell tumor of bone in the denosumab era
    Nagano, Akihito
    Urakawa, Hiroshi
    Tanaka, Kazuhiro
    Ozaki, Toshifumi
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (05) : 411 - 416